RenovoRx, Inc. (RNXT) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
4.55
↓-29% vs avg
5yr avg: 6.45
30Y Low5.6·High6.9
ROE
↑
-1192.7%
↑-27% vs avg
5yr avg: -939.2%
30Y Low-262%·High-92%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RNXT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
RenovoRx, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $32M | $30M | $47M | $43M | $86M | — | — |
| Enterprise Value | $25M | $24M | $46M | $38M | $71M | — | — |
| P/E Ratio → | -2.33 | — | — | — | — | — | — |
| P/S Ratio | 736.07 | 708.18 | — | — | — | — | — |
| P/B Ratio | 4.55 | 6.80 | — | 6.90 | 5.63 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RNXT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 548.27 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
RNXT Profitability
Margins and return-on-capital ratios measuring operating efficiency
RenovoRx, Inc. earns an operating margin of -25511.6%. A negative ROE of -1192.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | -25511.6% | -25511.6% | — | — | — | — | — |
| Net Profit Margin | -20497.7% | -20497.7% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -1192.7% | -1192.7% | -647.0% | -91.9% | -1825.1% | — | -262.0% |
| ROA | -183.9% | -183.9% | -234.4% | -84.0% | -69.5% | -181.5% | -169.1% |
| ROIC | — | — | — | -773.7% | — | — | — |
| ROCE | -337.5% | -337.5% | -353.1% | -92.5% | -86.1% | — | -265.9% |
RNXT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $7M exceeds total debt of $278000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.54 | — | -0.71 | -0.99 | — | -1.44 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -105.52 | -174.56 | -6.80 | -5.43 | — |
Net cash position: cash ($7M) exceeds total debt ($278000)
RNXT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
RenovoRx, Inc.'s current ratio of 4.10x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 6.59x to 4.10x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 4.10 | 4.10 | 1.25 | 6.59 | 17.36 | 0.47 | 2.81 |
| Quick Ratio | 4.10 | 4.10 | 1.25 | 6.59 | 17.36 | 0.47 | 2.81 |
| Cash Ratio | 3.75 | 3.75 | 1.00 | 5.84 | 16.20 | 0.44 | 2.61 |
| Asset Turnover | — | 0.01 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 365.00 | — | — | — | — | — |
RNXT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
RenovoRx, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $24M | $21M | $18M | $18M | $17M | $17M |
Peer Comparison
Compare RNXT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RNXTYou | $32M | -2.3 | — | — | 100.0% | -25511.6% | -1192.7% | — | — |
 NKTR | $2B | -8.4 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 CRIS | $74M | -1.0 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 TPVG | $234M | 4.7 | 9.0 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 IMVT | $6B | -10.6 | — | — | — | — | -62.5% | — | — |
 CASI | $2M | -0.1 | — | — | 39.1% | -138.8% | -301.8% | -153.0% | — |
 HALO | $8B | 25.0 | 8.2 | 11.7 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 NVCR | $2B | -14.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 ARDX | $2B | -26.1 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 TGTX | $7B | 15.5 | 56.9 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See RNXT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNXT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RNXT vs NKTR
Side-by-side business, growth, and profitability comparison vs Nektar Therapeutics.
Start ComparisonRNXT — Frequently Asked Questions
Quick answers to the most common questions about buying RNXT stock.
What is RenovoRx, Inc.'s P/E ratio?
RenovoRx, Inc.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
What is RenovoRx, Inc.'s ROE?
RenovoRx, Inc.'s return on equity (ROE) is -1192.7%. The historical average is -177.0%.
Is RNXT stock overvalued?
Based on historical data, RenovoRx, Inc. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are RenovoRx, Inc.'s profit margins?
RenovoRx, Inc. has 100.0% gross margin and -25511.6% operating margin.